Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Bio-Rad Laboratories (BIO)

Bio-Rad Names Jonathan DiVincenzo President and Chief Operating Officer, Effective September 9

Neutral Impact 4 of 5 leadership Written later

Bio-Rad Laboratories appointed Jonathan P. DiVincenzo, formerly an executive at Labcorp, as President and Chief Operating Officer, effective September 9, 2024, replacing Andrew Last, who retires September 5, 2024. CEO Norman Schwartz keeps his role as Chief Executive Officer and Chairman and gives up the title of President.

Key points

  • DiVincenzo's offer letter provides a $665,000 annual base salary and a 2024 target cash bonus of 100% of eligible earnings.
  • Equity and sign-on terms include restricted stock units valued at $2,500,000 within sixty days of hire and a $1.3 million sign-on bonus payable by February 15, 2025.
  • DiVincenzo was most recently Executive Vice President and President, Central Laboratories & International at Labcorp from May 2023 to August 2024.

The filing

CompanyBio-Rad Laboratories (BIO)
Form8-K, current report
Filed with the SECAug 20, 2024, 8:30 AM ET
Accession number0000012208-24-000054

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:56 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 20, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.